Fabian Lang, MD, Goethe University, Frankfurt, Germany, comments on the tolerability and efficacy of asciminib in the treatment of patients with chronic myeloid leukemia (CML) in the third-line setting, highlighting the importance of improving the outcomes of this patient population and achieving a higher rate of treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
F.L. receives support from the Frankfurter Förderung “Nachwuchswissenschaftler” and the EUTOS funding program. F.L had advisory roles for Novartis, Incyte, Sanofi Aventis and Bristol-Myers Squibb. F.L. received funding from Novartis.